Clinical trials: Primary CNS Lymphoma (PCNSL)
PCNSL
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing zanubrutinib on the basis of rituximab and methotrexate (MTX) [or temozolomide (TMZ), if intolerant to MTX] in…
- Trial name
- NCT05896007
- Testing
- Zanubrutinib, Rituximab, Methotrexate
- Where
- China
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity
- Trial name
- NCT00734773
- Testing
- Rituximab, Cytarabine, Methotrexate
- Sponsor
- Northwestern University
Primary Central Nervous System Lymphoma (PCNSL)
Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
This study aims to evaluate the efficacy and safety of the VPX regimen, a novel combination of teniposide, PD-1 monoclonal antibody and selinexor, in patients with relapsed/refractory (R/R) primary central nervous system lymphoma…
- Trial name
- VPX (NCT07074470)
- Testing
- Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor), Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning, Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, Non-Hodgkin, HIV Infections
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide…
- Trial name
- NCT00000801
- Testing
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leukemia, Lymphoma
Interferon Alfa in Treating Children With HIV-Related Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's…
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00002621
- Testing
- recombinant interferon alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Children's Oncology Group
Diffuse Large B-cell-lymphoma
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix)…
- Trial name
- MATRix (NCT02531841)
- Testing
- Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®), Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
- Where
- 2 sites in Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital Freiburg
Lymphoma
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
The purpose of this study is to evaluate two types of chemotherapy for primary central nervous system lymphoma in the elderly (age older than 60) : Methotrexate, procarbazine, vincristine and cytarabine Methotrexate and…
- Trial name
- CNSLymphoma (NCT00503594)
- Testing
- Methotrexate and temozolomide, Methotrexate , procarbazine ,vincristine ,cytarabine
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary CNS Lymphoma
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
The purpose of this study is to determine the efficacy and safety of the new treatment proposed in this study. Conducting a prospective study "CNS-2015" in patients with PDLBCL CNS made it possible to achieve 2-year EFS, DFS and…
- Trial name
- NCT05425654
- Testing
- Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Primary Central Nervous System Lymphoma
First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)
Exploring the efficacy and safety of first-line treatment of primary central nervous system lymphoma with the combination of orelabrutinib, rituximab and methotrexate (ORM regimen).
- Trial name
- NCT06454266
- Testing
- ORM regimen
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Ningbo No. 1 Hospital
Central Nervous System Lymphoma
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with central nervous system (CNS) lymphoma.
- Trial name
- NCT05625594
- Testing
- Aspiration, Biospecimen Collection, Catheterization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Primary Central Nervous System Lymphoma
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
This is a three-arm, multicenter, randomized controlled trial. Eligible participants will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio.
- Trial name
- NCT07185373
- Testing
- Teniposide, Orelabrutinib, MTX
- Where
- 15 sites in China
- Volunteers
- 215 people
- Sponsor
- Huashan Hospital
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose…
- Trial name
- NCT04947319
- Testing
- Tirabrutinib
- Where
- 39 sites in United States
- Volunteers
- 119 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Primary CNS Lymphoma
[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
This study was conducted to evaluate the 2-year progression free survival rate of elderly patients with primary CNS lymphoma followed by combination of rituximab and methotrexate followed by rituximab and cytarabine.
- Trial name
- NCT03569995
- Testing
- Rituximab, Methotrexate, Cytarabine Injection
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Won Seog Kim
Primary Central Nervous System Lymphoma
Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
In summary, there is a high medical need for patients suffering from recurrent/progressive PCNSL. Targeting the PD-1 pathway may represent a very promising novel approach for the treatment of these patients.
- Trial name
- NCT02779101
- Testing
- pembrolizumab
- Where
- Austria
- Volunteers
- 21 people
- Sponsor
- Prof. Dr. Matthias Preusser
CNS Lymphoma
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
- Trial name
- CLIMB (NCT05828628)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Lymphoma, Small Intestine Cancer
ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00016172
- Testing
- pegylated liposomal doxorubicin hydrochloride, picoplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center